Pityriasis rubra pilaris following COVID-19 vaccination successfully treated with ixekizumab

Zhao, Patricia; Rusu, Corina A.; Schenck, Olivia L

doi:10.1016/j.jdcr.2023.03.003

Cited by 6 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 54-year-old female with PRP had near-complete resolution after 2 months of treatment with ixekizumab. 20 In a 53-year-old male with PRP and HIV, a 50% reduction in erythema was achieved after 1 week of treatment with ixekizumab. 21 Resolution of erythema and a decrease in pruritus was achieved in a 67-year-old male after 16 weeks of treatment with ixekizumab.…”

Section: Resultsmentioning

confidence: 99%

Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review

Chandy,

Chokshi,

Tan

et al. 2024

J Cutan Med Surg

View full text Add to dashboard Cite

Objective: To describe the published efficacy and adverse event rates associated with existing biologics for the treatment of pityriasis rubra pilaris (PRP). Data Sources: A literature review using the PubMed database (January 1990-July 2023) was conducted. Multiple search combinations were conducted using “pityriasis rubra pilaris” and various biologics as keywords to identify relevant articles. Study Selection and Data Extraction: Inclusion criteria included all study types that were published within the past 30 years in English and mentioned at least one biologic and PRP. A preliminary search yielded a total of 499 results. After screening using inclusion and exclusion criteria, 77 relevant articles (69 case reports, 5 case series, 2 clinical trials, and 1 retrospective analysis) were analyzed. Data Synthesis: TNF-α inhibitors have been evaluated and are effective in treating PRP. However, recent treatment with anti-interleukin (IL)-17 and anti-IL-23 therapies such as ustekinumab, secukinumab, and ixekizumab are emerging as new treatment options with a mean improvement in PRP Area and Severity Index scores, change in severity of erythema, scaling, and thickness of PRP lesions. From initial clinical trials, secukinumab and ixekizumab are promising treatment options for achieving remission. Relevance to Patient Care and Clinical Practice: This review compares the efficacy for numerous biologics and a discussion to guide clinicians on benefits and risks in choosing a biologic for PRP patients. Conclusions: Biologics may be a favourable treatment option leading to greater patient adherence due to reduced dosing frequencies, improvement in quality of life, and reduction in frequency and severity of flares.

show abstract

Section: Resultsmentioning

confidence: 99%

Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review

Chandy,

Chokshi,

Tan

et al. 2024

J Cutan Med Surg

View full text Add to dashboard Cite

show abstract

“…There are literature reports describing the association between the onset of PRP and treatment with tyrosine kinase inhibitors, topical TLR agonists, phosphatidylinositol-3-kinase inhibitors, antivirals, biologics, PD-1 inhibitors, VEGF inhibitors, statins, insulins, angiotensin-converting enzyme inhibitors, and COVID-19 vaccines [35,36]. There have also been sporadic reports linking PRP with autoimmune diseases and cancer [1].…”

Section: Discussionmentioning

confidence: 99%

Pityriasis rubra pilaris secondary to viral infection

Pawlik,

Jarosz-Chudek,

Dyduch

et al. 2023

View full text Add to dashboard Cite

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) Dermatology Review/Przegląd Dermatologiczny 2023/5 620 of Dermatology (OKD) of the University Hospital in Krakow, who developed symptoms of PRP after a viral infection, and provide insights into the nature of the disease. Case reportA 67-year-old male patient, a retired entrepreneur, was admitted to the OKD for the diagnosis and treatment of rapidly progressive erythematous papular skin rash. The first skin lesions, presenting as erythema on the face and palms, appeared approximately 2 weeks prior to hospitalisation. Subsequently, ery-abstraCt Introduction: Pityriasis rubra pilaris is a rare, chronic dermatosis presenting with erythema and papular eruptions as well as characteristic perifollicular hyperkeratosis and 'islands of sparing' (normal appearing skin). In the literature, there are reports of cases where symptoms of infection preceded the onset of pityriasis rubra pilaris. Objective: Presentation of the case of a 67-year-old patient with type I pityriasis rubra pilaris to highlight the possible association between pityriasis rubra pilaris with infectious agents. Case report: A 67-year-old patient was referred to hospital because of rapidly progressive erythematous papular skin rash preceded by symptoms of an upper respiratory tract infection. On physical examination, attention was drawn to perifollicular papules covered with cap-like scales as well as confluent erythema and features of hyperkeratosis on the hands and feet. Based on the clinical presentation and histopathological findings, type I pityriasis rubra pilaris was diagnosed and treatment with acitretin was initiated. Conclusions: Infectious agents have the potential to be a trigger for pityriasis rubra pilaris. Acitretin continues to demonstrate efficacy in the treatment of pityriasis rubra pilaris.

show abstract

“…Ixekizumab and ustekinumab have also been reported in the literature as successful therapies for SARS-CoV-2 vaccine-induced PRP. 1 , 3 , 6 We report a case of new-onset severe erythrodermic PRP after the Moderna SARS-CoV-2 vaccination, treated with selective IL-17A and IL-17F inhibition.…”

Section: Introductionmentioning

confidence: 96%

“…SARS-CoV-2 vaccinations have been linked to several cutaneous adverse effects, including psoriasiform dermatoses, such as pityriasis rubra pilaris (PRP). 1 , 2 , 3 PRP is a rare inflammatory papulosquamous disorder of unclear etiology. The interleukin (IL) 23/Th17 axis is thought to play a role in the pathophysiology of PRP.…”

Section: Introductionmentioning

confidence: 99%

Pityriasis rubra pilaris following COVID-19 vaccination successfully treated with ixekizumab

Cited by 6 publications

References 21 publications

Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review

Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review

Pityriasis rubra pilaris secondary to viral infection

Erythrodermic pityriasis rubra pilaris following SARS-CoV-2 vaccination treated with bimekizumab

Contact Info

Product

Resources

About